Ascletis Pharma Inc.

1672

KYG0520K1094

Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ascletis Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.24 CNY

Average target price

2.752 CNY

Spread / Average Target

+121.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ASCLETIS PHARMA INC.	-8.22%	176M
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.42B
BIOGEN INC.	-19.27%	29.48B
UCB	+57.86%	25.43B
INCYTE CORPORATION	-17.69%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.34 ^HKD	-1.47%		+5.51%	-8.22%

Apr. 03	Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	MT
Apr. 03	Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	CI

Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	Apr. 03	MT
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	Apr. 03	CI
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting	Mar. 10	CI
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug	Jan. 24	MT
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne	Jan. 24	CI
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial	Jan. 03	MT
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis	Jan. 02	CI
Ascletis Pharma Gets Nod to Trial Acne Drug	Dec. 05	MT
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne	Dec. 05	CI
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet	Nov. 13	MT
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication	Nov. 06	MT
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug	23-10-10	MT
Ascletis Pharma Finds Envafolimab Safe to Use in Study	23-09-29	MT
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure	23-09-28	CI
Ascletis Enrolls 120 Patients in Phase 3 Clinical Trial for Combination Treatment for Glioblastoma; Shares Fall 6%	23-09-26	MT
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma	23-09-25	CI
Ascletis' H1 Attributable Loss Narrows as Revenue Jumps	23-08-21	MT
Ascletis Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Ascletis Pharma's HIV Drug Clinical Data Presented at Australia Medical Conference	23-07-25	MT
Ascletis Unit Completes Patient Enrollment for Phase 2 Trial for Biliary Cholangitis Drug; Shares Rise 8%	23-07-20	MT
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis	23-07-19	CI
Ascletis Pharma to Shrink Loss in H1	23-07-18	MT
Ascletis Pharma Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2023	23-07-18	CI
Ascletis Pharma Inc. commences an Equity Buyback Plan for 108,713,400 shares, representing 10% of its issued share capital, under the authorization approved on June 29, 2023.	23-06-30	CI